AdBio partners

Cephagenix focuses on identifying and developing new, effective migraine therapies.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.

Orikine Bio is an innovative biotechnology company specializing in tailored cytokines for treating immune-mediated disorders. The company has developed a proprietary platform focused on cytokine-based therapies aimed at addressing autoimmune and inflammatory diseases. Orikine Bio's approach emphasizes the advancement of engineered cytokines with unique biological properties, which are designed to offer transformative treatment options. By leveraging its novel platform, Orikine Bio strives to create therapies that can significantly improve the lives of patients worldwide.

Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

DiogenX is a preclinical stage biotech company based in Marseille, France, with research labs in Nice. Founded in 2019, the company specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of Type 1 and Type 2 diabetes. DiogenX aims to create a candidate molecule that regenerates insulin-producing pancreatic cells, potentially improving the quality of life and survival rates for individuals with diabetes. The innovative therapy is based on research conducted in the laboratory of Dr. Patrick Collombat, which positions DiogenX as a pioneer in the development of beta-cell regeneration treatments for diabetes.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Calida Therapeutics is a biotechnology company focused on addressing thrombo-inflammatory disorders and vascular diseases. The company specializes in the development of monoclonal antibodies designed to treat and prevent these conditions by disrupting the molecular connection between thrombosis and inflammation. By preventing the interaction between platelets and myeloid cells, Calida Therapeutics aims to protect patients from tissue damage and serious health risks associated with thrombo-inflammatory disorders.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at treating autoimmune diseases and inflammatory disorders. The company has created a peptide that preserves a cluster of truncated CD31 molecules at the membrane, allowing for the moderation of overactive immune responses without complete blockade. This innovative approach enables medical companies to provide enhanced therapeutic options, ultimately improving patient outcomes and quality of life.

Integra Therapeutics is focused on advancing gene editing technologies to address various diseases. The company is developing innovative gene writing tools that aim to enhance the effectiveness of gene therapy. By combining the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in the field of gene editing. This approach allows scientists to introduce DNA into a genome using sequence-specific DNA binding proteins, thereby facilitating the development of targeted gene therapies that meet the specific needs of patients.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Thabor Therapeutics is a biotechnology company focused on developing innovative treatments for mucosal inflammatory diseases. The company targets a new class of proteins involved in the resolution of inflammation, utilizing monoclonal antibodies to address these conditions. By inhibiting specific targets implicated in early inflammatory processes and the recruitment of innate immune cells, Thabor Therapeutics aims to provide effective therapies that enable healthcare providers to improve patient outcomes.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

DiogenX is a preclinical stage biotech company based in Marseille, France, with research labs in Nice. Founded in 2019, the company specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of Type 1 and Type 2 diabetes. DiogenX aims to create a candidate molecule that regenerates insulin-producing pancreatic cells, potentially improving the quality of life and survival rates for individuals with diabetes. The innovative therapy is based on research conducted in the laboratory of Dr. Patrick Collombat, which positions DiogenX as a pioneer in the development of beta-cell regeneration treatments for diabetes.

Wellium SAS, established in 2016 and headquartered in Levallois-Perret, France, specializes in digital transformation tools for the medical sector. The company provides teleconsultation solutions aimed at improving healthcare access and efficiency. Its flagship products include Feelae, an application that enables patients to receive medical care remotely, addressing issues such as medical desertification and overcrowding in emergency services, and Leah, a teleconsultation platform designed specifically for healthcare professionals to consult with their patients online. Through these innovations, Wellium aims to enhance the overall healthcare experience for both patients and doctors.

Alderaan Biotechnology is a biotechnology company focused on developing innovative antibodies for cancer treatment, specifically targeting new and original immuno-oncology targets expressed by Natural Killer (NK) cells. The company specializes in monoclonal antibodies that aim to deplete regulatory T (Treg) cells within the tumor microenvironment, thereby enhancing the cytotoxic activity of NK cells. By creating these targeted therapies, Alderaan Biotechnology seeks to provide physicians with effective tools to improve cancer treatment outcomes through advanced immunotherapy approaches.

Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.

Urania Therapeutics is a biopharmaceutical company focused on developing innovative therapies for genetic diseases and cancers caused by mutations. The company specializes in the identification and creation of readthrough compounds that address premature stop codons during protein synthesis. By facilitating the production of full-length proteins, these compounds aim to treat a variety of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its unique structure-based drug design platform, Urania Therapeutics seeks to restore the production of functional proteins, thereby offering new therapeutic options for patients with these challenging conditions.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at treating autoimmune diseases and inflammatory disorders. The company has created a peptide that preserves a cluster of truncated CD31 molecules at the membrane, allowing for the moderation of overactive immune responses without complete blockade. This innovative approach enables medical companies to provide enhanced therapeutic options, ultimately improving patient outcomes and quality of life.

Yukin Therapeutics is a French biotechnology company specializing in the development of kinase inhibitors aimed at targeting the NIK protein, which plays a critical role in the progression of various cancers. The company is focused on creating therapeutic molecules that modify the tumor microenvironment, facilitating immune system infiltration to enhance the efficacy of existing cancer immunotherapies. Yukin Therapeutics has successfully conducted studies demonstrating proof of concept in animal models and is now in the process of identifying a first drug candidate for clinical trials in oncology, with the goal of improving treatment options for cancers such as skin and pancreatic cancer.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Alderaan Biotechnology is a biotechnology company focused on developing innovative antibodies for cancer treatment, specifically targeting new and original immuno-oncology targets expressed by Natural Killer (NK) cells. The company specializes in monoclonal antibodies that aim to deplete regulatory T (Treg) cells within the tumor microenvironment, thereby enhancing the cytotoxic activity of NK cells. By creating these targeted therapies, Alderaan Biotechnology seeks to provide physicians with effective tools to improve cancer treatment outcomes through advanced immunotherapy approaches.